Metal-free alkene carbooxygenation following tandem intramolecular alkoxylation/Claisen rearrangement: stereocontrolled access to bridged [4.2.1] lactones†

Long Li,a Xin-Qi Zhu,a Ying-Qi Zhang,a Hao-Zhen Bu,a Peng Yuan,a Jinyu Chen,b Jingyi Su,b Xianming Dengb and Long-Wu Yeac

Alkene carbooxygenation has attracted considerable attention over the past few decades as this approach provides an efficient access to various oxygen-containing molecules, especially the valuable O-heterocycles. However, examples of catalytic alkene carbooxygenation via a direct C–O cleavage are quite scarce, and the C–O cleavage in these cases is invariably initiated by transition metal-catalyzed oxidative addition. We report here a novel Brønsted acid-catalyzed intramolecular alkoxylation-initiated tandem sequence, which represents the first metal-free intramolecular alkoxylation/Claisen rearrangement. Significantly, an unprecedented Brønsted acid-catalyzed intramolecular alkene insertion into the C–O bond via a carbocation pathway was discovered. This method allows the stereocontrolled synthesis of valuable indole-fused bridged [4.2.1] lactones, providing ready access to biologically relevant scaffolds in a single synthetic step from an acyclic precursor. Moreover, such an asymmetric cascade cyclization has also been realized by employing a traceless chiral directing group. Control experiments favor the feasibility of a carboxylation pathway for the process. In addition, biological tests showed that some of these newly synthesized indole-fused lactones exhibited their bioactivity as antitumor agents against different breast cancer cells, melanoma cells, and esophageal cancer cells.

Introduction

Bridged [4.2.1] lactones are widely distributed heterocycles found in various natural products such as hushinone and citrinovirin, and bioactive compounds (Fig. 1). However, such bicyclic frameworks bearing both a medium ring and bridged unit are regarded as difficult skeletons to construct due to entropic effects and the ring strain factor, and very few methods have been reported to date. Hence, novel and stereocontrolled synthesis of bridged [4.2.1] lactone motifs allowing structurally diverse modification is in great demand in both organic and medicinal chemistry.

Fig. 1 Selected bioactive molecules containing bridged [4.2.1] lactones.
oxidative addition (Scheme 1a). For example, Douglas et al. reported an elegant protocol for the rhodium-catalyzed intramolecular alkene oxygenation reaction via an acyl C–O bond activation. In 2012, Nakao et al. disclosed an intramolecular oxyacetylene of alkenes by palladium/BPh₃ catalysis. Thus, the development of an alternative approach for the catalytic cleavage of the C–O bond and the addition reaction to the alkene is highly desirable.

Because of their high bond-forming efficiency and atom economy, catalytic tandem intramolecular alkylcarbonylation/Claissen rearrangements have received significant attention. In particular, such a cascade cyclization of alkynyl allyl ethers could lead to the formation of various valuable O-heterocycles, which is also established by Hashmi, Liu, Gagosz, Miyata, and others (Scheme 1a). While these achievements are impressive, almost all of these approaches rely on the use of noble metals such as gold and platinum as catalysts. In our recent study on the catalytic tandem reactions of ynamides for heterocycle synthesis, we realized the first metal-free intramolecular alkylcarbonylation/Claissen rearrangement of indole-linked ynamide-allyl ethers (Scheme 1b). Interestingly, the resulting six-membered lactone intermediate further underwent an unprecedented Bronsted acid-catalyzed intramolecular carbooxylation of olefins by C–O bond cleavage involving ring opening, carboxylation rearrangement, and then ring closing. This Bronsted acid catalysis led to the highly efficient and stereocontrolled formation of valuable indole-fused bridged lactones. Furthermore, such an asymmetric cascade cyclization was also realized by employing a traceless chiral directing group. The mechanistic rationale for this cascade reaction is strongly supported by a variety of control experiments. In this paper, we wish to report the results of our detailed investigations of this novel cascade cyclization, including the substrate scope, synthetic applications, biological tests and mechanistic studies.

Results and discussion

Inspired by our previous work on the indolyl ynamide chemistry, we chose an indole-tethered ynamide 1a as the model substrate for the initial study. As shown in Table 1, indole-fused lactone 2aa was obtained in the presence of most non-noble metals (Table 1, entries 1–4), with Cu(OTf)₂ giving the best yield of the desired 2aa (Table 1, entry 4). Different from Hashmi’s protocol, N-methyl methanesulphonamide here not only serves as the directing group to achieve regioselective attack at the N-terminus of alkyne, but also can be removed spontaneously and regarded as a traceless directing group. Surprisingly, indole-fused bridged lactone 2a was detected as the main product by employing In(OTf)₃ or Fe(OTf)₃ as catalysts (Table 1, entries 5–6). Of note, typical gold catalysts, such as Ph₃PAuNTf₂ and IPrAuNTf₂, were not effective in promoting this reaction and the decomposition of 1a was observed in these cases (Table 1, entries 7–8). Various Bronsted acids were also evaluated, but typical organic acids (e.g., TFA, MsOH, and TsOH) were not capable of catalyzing the reaction. Gratifyingly, HOTf and HNTf₂ (Table 1, entries 9–10) could effectively catalyze this cascade cyclization and the bridged lactone 2aa was obtained in 81% yield in the latter case (Table 1, entry 10). The reaction proved to be less efficient when it was performed at 60 °C (Table 1, entry 11) or in other solvents. The observed excellent efficiency with HNTf₂ as the catalyst can be explained by its high Bronsted acidity combined with the low nucleophilicity of its counterion.

Table 1 Optimization of reaction conditions

| Entry | Catalyst | Reaction conditions | Yield (%) |
|-------|----------|---------------------|----------|
| 1     | Y(OTf)₃  | DCE, 40 °C, 48 h    | <1       |
| 2     | Yb(OTf)₃ | DCE, 40 °C, 48 h    | <1       | 20   | 75  |
| 3     | Zn(OTf)₂ | DCE, 40 °C, 48 h    | <1       | 50   | 30  |
| 4     | Cu(OTf)₂ | DCE, 40 °C, 48 h    | <1       | 70   | 25  |
| 5     | In(OTf)₃ | DCE, 40 °C, 48 h    | <1       | 84   | <1  |
| 6     | Fe(OTf)₃ | DCE, 40 °C, 48 h    | <1       | 63   | 15  |
| 7     | Pb_PAuNTf₂| DCE, rt, 10 h      | <1       | <1   | <1  |
| 8     | IPrAuNTf₂| DCE, rt, 10 h      | <1       | <1   | <1  |
| 9     | HOTf     | DCE, 40 °C, 24 h    | <1       | 72   | 17  |
| 10    | HNTf₂    | DCE, 40 °C, 24 h    | 81       | <1   | <1  |
| 11    | HNTf₂    | DCE, 60 °C, 18 h    | 67       | <1   | <1  |

* Reaction conditions: 1a (0.1 mmol), catalyst (0.02 mmol), DCE (2 mL), 40–60 °C, in vials. Measured by ¹H NMR using diethyl phthalate as the internal standard. ⁵ 5 mol% of catalyst was used.
With the optimal reaction conditions in hand (Table 1, entry 10), the scope of this novel tandem reaction was explored (Table 2). This metal-free cascade cyclization proceeded efficiently to furnish a series of indole-fused bridged [4.2.1] lactones in mostly good to excellent yields. For instance, various indolyl-substituted ynamides bearing both electron-donating and - withdrawing groups could be readily converted into the desired indole-fused bicyclic skeletons 2a–2p with yields ranging from 60% to 86%. In particular, the functional groups, such as CF3, CN and CO2Me, were well tolerated under this Brønsted acid catalysis. Further investigation of N-protecting groups demonstrated that the B5s and Ms-protected substrates 1q–1r gave slightly improved yields. In addition, an ynamide with a methyl group (R1 = Me) was also a suitable substrate for this tandem reaction to afford the corresponding 2s in 63% yield (dr: 4 : 1). This result clearly indicated that [3,3] rearrangement, but not [1,3] rearrangement, was presumably involved in this multiple cascade sequence. Furthermore, the reaction also occurred smoothly with various aryl- or methyl-substituted ynamides (R2 = aryl, Me), and the desired 2t–2z containing a quaternary carbon center could be formed in 60–75% yields by employing 30 mol% of HNTf2 as the catalyst. Importantly, excellent diastereoselectivity (>20 : 1) was achieved in all cases except for the substrate 1s. The molecular structures of 2a, 2s and 2u were confirmed by X-ray diffraction. Thus, this metal-free protocol provides a highly convenient and practical route for the preparation of valuable bridged [4.2.1] lactones.

In addition, this multiple cascade reaction was also applicable to other electron-rich aromatic ring-substituted ynamides such as benzofuran-, pyrrole-, and alkoxy arene-tethered ynamides 3a–3c, delivering the desired bridged [4.2.1] lactones 4a–4c in serviceable yields with excellent dr values (>20 : 1), as depicted in eqn (1)–(3). Of note, the use of HFIP as an additive led to a significantly improved yield in the case of 3c (eqn (3)). Attempts to extend the reaction to non-terminal alkene-substituted ynamide 3d, indole-linked ynamide-allyl amine 3e and sulfide 3f led to the formation of complicated mixtures.

Table 2 Reaction scope for the construction of bridged [4.2.1] lactones a

| R1 | R2 | R3 | PG | HNTf2 (20 mol %) | DCE, 40 °C, 24 h | Yields |
|----|----|----|----|-----------------|-----------------|--------|
| R1 | R2 | R3 | PG | HNTf2 (20 mol %) | DCE, 40 °C, 24 h | Yields |
|----|----|----|----|-----------------|-----------------|--------|
| Me | HNTf2 (20 mol %) | DCE, 40 °C, 24 h | Yields |
|----|-----------------|-----------------|--------|
| 2a  | 77% |
| 2b  | 65% |
| 2c  | 66% |
| 2d  | 73% |
| 2e  | 66% |
| 2f  | 70% |
| 2g  | 78% |
| 2h  | 86% |
| 2i  | 60% |
| 2j  | 86% |
| 2k  | 80% |
| 2l  | 70% |
| 2m  | 81% |
| 2n  | 80% |
| 2o  | 72% |
| 2p  | 78% |
| 2q  | 83% |
| 2r  | 60% |
| 2s  | 63% (dr: 4 : 1) |
| 2t  | 68% |
| 2u  | 75% |
| 2v  | 60% |
| 2w  | 66% |
| 2x  | 64% |
| 2y  | 61% |
| 2z  | 67% |

a Reaction conditions: 1 (0.2 mmol), HNTf2 (0.04 mmol), DCE (4 mL), 40 °C, in vials; yields are those for the isolated products. b 80 °C, 36 h. c 48 h. d 30 mol% of HNTf2 was used, 60 °C, 24 h.
Although our attempts to employ various chiral Brønsted acids such as chiral phosphoric acids and chiral phosphoric amides to catalyze this cascade cyclization failed probably due to the fact that their acidity is not strong enough, the chiral bridged [4.2.1] lactones could be synthesized by employing a chiral oxazolidinone instead of N-methyl methanesulfonamide as the directing group.24 As shown in eqn (4), it was found that the tert-butyl substituted oxazolidinone-derived chiral ynamide 5d gave the best enantioselectivity, and the desired chiral bridged [4.2.1] lactone 2a-ent was formed in 55% yield with 95% ee in the presence of 30 mol% of HNTf2 as the catalyst and 1.5 equiv. of water as the additive. Thus, the chiral auxiliary can be regarded as a traceless directing group to introduce the chirality in a very facile manner. It should be mentioned that significant racemization was observed when prolonging the reaction time.\(^1\)

The scope of this asymmetric intramolecular alkoxylation-initiated tandem reaction was further examined by using tert-butyl substituted oxazolidinone-derived chiral ynamides. As depicted in Table 3, the reaction proceeded smoothly with various chiral ynamides 5, allowing the facile synthesis of the corresponding enantioenriched bridged [4.2.1] lactones 2-ent in serviceable yields with excellent ee values (91–99% ee) and excellent dr values (>20 : 1). Of note, (R)-tert-butyl substituted oxazolidinone-derived chiral ynamide 5d could also undergo smooth cascade cyclization to deliver the desired 2a-ent’ with the opposite enantioselectivity.

The potential synthetic utility of this protocol was then demonstrated by the facile diversification of bridged lactone 2a, and importantly, excellent diastereoselectivity was achieved in all cases (Scheme 2). For example, the Ts group in lactone 2a, prepared on a gram scale in 72% yield, was easily removed by treatment with TBAF to afford the corresponding 2ab in 75% yield. In addition, the lactone part of 2a could be selectively reduced to furnish the hemiacetal 2ac (91%, dr > 10 : 1) with DIBAL-H. By contrast, the use of Et3SiH led to the total reduction of the lactone to produce the desired 2ad in almost quantitative yield. Interestingly, 2a could also be oxidized with DDQ to deliver 2ae in 95% yield. Moreover, the ring of lactone 2a was readily opened by employing PhLi, leading to the stereocontrolled construction of cyclohept[b]indole scaffold 2af, frequently occurring in natural products and bioactive molecules.21 Finally, the chiral 2a-ent could be further transformed into the indole-fused cycloheptanone 2ah with the ee maintained, and its structure was confirmed by X-ray diffraction,\(^1\) which also determined the absolute configuration of 2a-ent.\(^2\)

Considering the bioactivity reported in the literature for bridged [4.2.1] lactone systems,\(^1\) we also tested the above

---

**Table 3** Reaction scope for the construction of chiral bridged [4.2.1] lactones 2-ent\(^a\)

![Chemical structure](image)

\(^a\) Reaction conditions: 5 (0.2 mmol), HNTf2 (0.06 mmol), water (0.3 mmol), dry DCE (2 mL), 30 °C, in vials; yields are those for the isolated products; determined by HPLC analysis. \(^b\) 40 °C, 20 min. \(^c\) 30 min. \(^d\) Using (R)-configured ynamide 5d as the substrate.

---

**Scheme 2** Gram scale reaction and synthetic applications. Reagents and conditions: (i) TBAF (4 equiv.), THF, 65 °C, 6 h; (ii) DIBAL-H (1.5 equiv.), THF, –78 °C, 6 h; (iii) InBr3 (0.5 equiv.), Et3SiH (2.5 equiv.), CHCl3, 60 °C, 10 h; (iv) DDQ (3 equiv.), DCE, 60 °C, 48 h; (v) PhLi (1.2 equiv.), THF, –40 °C, 2 h; –20 °C, 10 h.
synthesized indole-fused lactones for their biological activity as antitumor agents. The cytotoxic effects of these compounds were evaluated against a panel of cancer cells, including breast cancer cells MDA-MB-231 and MCF-7, melanoma cells A375, and esophageal cancer cells SK-GT-4 and KYSE-450 using cell viability assay. The results revealed that these compounds exhibited differential cytotoxicity and selectivity. Compounds 2k, 2l, and 2o selectively inhibited the cell growth of A375 by more than 50% at a concentration of 20 μM, and compound 2af inhibited the cell growth of MCF7 by around 70%. While compound 2ae showed broad activity with a cell viability less than 50% against cancer cells MDA-MB-231, A375 and KYSE-450.

To understand the reaction mechanism, several control experiments were conducted. First, we performed deuterium labeling studies and found that no deuterium loss was observed, thus ruling out any possible reaction pathways involving a hydride shift (eqn (5)). Importantly, 2aa was readily converted into 2a in 95% yield in the presence of HNTf₂ while no 2a was formed without an acid catalyst, strongly supporting the notion that 2aa is the key intermediate for this tandem reaction (eqn (6)). In addition, the formation of cyclohepta[8]indole 2ai (dr > 20 : 1) was detected when 2aa was treated with 10 equiv. of MeOH in the presence of HNTf₂, which indicates that the cationic intermediate is presumably involved in such a tandem sequence (eqn (7)). Of note, 2a could not be converted into 2ai in the presence of HNTf₂ and MeOH. Moreover, the cascade cyclization of ynamide 3g or 3h under the standard conditions only led to the formation of the corresponding 4ga (42%) or 4ha (85%), and no desired bridged lactone product was observed (eqn (8) and (9)). These results further suggest that the intramolecular alkene insertion into the C–O bond proceeds via a carbocation pathway, and the generation of a stable electron-rich benzylic carbocation is the key for this lactone expansion process. Finally, it was found that significant incorporation of 18O (>85%) into the product 2a was observed in the presence of 18O-labelled water (10 equiv.), indicating that the oxygen atom on the carbonyl group of 2a originates from water.

Based on the above experimental observations, a plausible mechanism to rationalize the formation of indole-fused bridged [4.2.1] skeleton 2 is proposed (Scheme 3). Initially, the alkoxide group attacks the acid-activated ynamide 1 to form the Claisen rearrangement precursor A via a keteniminium intermediate, which undergoes typical [3,3] rearrangement and subsequent trapping by trace water, delivering the indole-fused lactone D[3129] (that is, 2aa in the case of substrate 1a) along with the generation of sulfonamide. Bronsted acid further promotes the ring opening of lactone D to produce the carbocation intermediate F via C–O bond cleavage. Finally, the carboxylation of F is trapped by an intramolecular electron-rich alkenyl group to generate another carbocation intermediate G, which is further captured by the intramolecular carboxylic acid group to afford the final product 2.[3127] Notably, the low nucleophilicity of Tf₂N⁻ might be important to maintain the cationic nature and/or reactivity of certain intermediates involved.

**Conclusions**

In summary, we have developed a novel Brønsted acid-catalyzed intramolecular alkoxylation-initiated tandem sequence, which represents the first metal-free intramolecular alkoxylation/Claisen rearrangement to the best of our knowledge. Significantly, an unprecedented Brønsted acid-catalyzed intramolecular alkene insertion into the C–O bond via a carbocation pathway was discovered, which may serve as an alternative approach for alkene carboxyoxgenation via a direct C–O cleavage. This method enables efficient and sterecontrolled access to
valuable indole-fused [4.2.1] lactones under mild reaction conditions, providing ready access to biologically relevant scaffolds in a single synthetic step from an acyclic precursor. Moreover, such an asymmetric cascade cyclization was also realized by employing a traceless chiral directing group. A mechanistic rationale for this novel tandem reaction is well supported by a variety of control experiments. In addition, our preliminary biological tests showed that some of these newly synthesized indole-fused lactones exhibited their bioactivity as antitumor agents against different breast cancer cells, melanoma cells, and esophageal cancer cells. Thus, we believe that this novel multiple cascade reaction will not only inspire chemists to design new rearrangement processes, but also encourage them to find their potential usefulness in organic and medicinal chemistry.

Conflicts of interest
There are no conflicts to declare.

Acknowledgements
We are grateful for the financial support from the National Natural Science Foundation of China (21772161 and 21622204), Fundamental Research Funds for the Central Universities (20720180036), PCSIRT, NFFITBS (11310024), Science & Technology Cooperation Program of Xiamen (3502ZZ20183015), Young Top-notch Talent Support Program of Fujian Province and XMU Undergraduate Innovation and Entrepreneurship Training Programs. We also thank Prof. Bijjie Li (Tsinghua University) and Prof. Zhenghu Xu (Shandong University) for valuable suggestions.

Notes and references
1 For selected examples, see: (a) D. A. Perrey, J.-X. Li and Y. Zhang, *Synthesis*, 2017, 49, 1394; (b) G. Ni, H. Zhang, Y.-Y. Fan, H.-C. Liu, J. Ding and J.-M. Yue, *Org. Lett.*, 2016, 18, 1880; (c) B. Ranieri, C. Obbradors, M. Mato and A. M. Echavarren, *Org. Lett.*, 2016, 18, 1614; (d) X.-R. Liang, F.-P. Miao, Y.-P. Song, X.-H. Liu and N.-Y. Ji, *Bioorg. Med. Chem. Lett.*, 2016, 26, 5029; (e) Y.-M. Shi, J. Yang, L. Xu, X.-N. Li, S.-Z. Shang, P. Cao, W.-L. Xiao and H.-D. Sun, *Org. Lett.*, 2014, 16, 1370; (f) Z.-B. Cheng, W.-W. Shao, Y.-N. Liu, Q. Liao, T.-T. Lin, X.-Y. Shen and S. Yin, *J. Nat. Prod.*, 2013, 76, 664; (g) T. Hirokawa and S. Kuwahara, *Eur. J. Org. Chem.*, 2013, 2780; (h) Z.-Y. Zhou, J.-G. Tang, F. Wang, Z.-J. Dong and J.-K. Liu, *J. Nat. Prod.*, 2008, 71, 1423; (i) A. G. González, T. Abad, I. A. Jiménez, A. G. Ravelo, J. G. Luis, Z. Aguiar, L. S. Andrés, M. Plasencia, J. R. Herrera and L. Moujir, *Biochem. Syst. Ecol.*, 1989, 17, 293.

2 (a) H. Liu, Y. Wang, X. Guo, L. Huo, Z. Xu, W. Zhang, S. Qiu, B. Yang and H. Tan, *Org. Lett.*, 2018, 20, 546; (b) W. Zhao, Z. Li and J. Sun, *J. Am. Chem. Soc.*, 2013, 135, 4680; (c) M. Szostak, L. Yao and J. Aubé, *J. Am. Chem. Soc.*, 2010, 132, 2078.

3 For recent examples, see: (a) Y.-L. Li, M.-C. Liu, Y.-J. Meng and L. Xu, *Tetrahedron*, 2016, 72, 3171; (b) M. Brambilla, S. G. Davies, A. M. Fletcher, P. M. Roberts and J. E. Thomson, *Tetrahedron*, 2014, 70, 204; (c) F. Grau, A. Heumann and E. Dübach, *Angew. Chem., Int. Ed.*, 2006, 45, 7285; (d) K. C. Nicolau, G. E. A. Careni and V. Jeso, *Angew. Chem., Int. Ed.*, 2005, 44, 3895.

4 For selected reviews, see: (a) X. Zhu and S. Chiba, *Chem. Soc. Rev.*, 2016, 45, 4504; (b) G. Yin, X. Mu and G. Liu, *Acc. Chem. Res.*, 2016, 49, 2413; (c) R. I. McDonald, G. Liu and S. S. Stahl, *Chem. Rev.*, 2011, 111, 2981; (d) F. Cardona and A. Goti, *Nat. Chem.*, 2009, 1, 269; (e) K. H. Jensen and M. S. Sigman, *Org. Biomol. Chem.*, 2008, 6, 4083.

5 For a review, see: J. P. Wolfe, *Angew. Chem., Int. Ed.*, 2012, 51, 10224.

6 (a) G. T. Hoang, V. J. Reddy, H. H. K. Nguyen and C. J. Douglas, *Angew. Chem., Int. Ed.*, 2011, 50, 1882; (b) G. T. Hoang, Z. Pan, J. T. Brethorst and C. J. Douglas, *J. Org. Chem.*, 2014, 79, 11383; (c) D. C. Koester, M. Kobayashi, D. B. Werz and Y. Nakao, *J. Am. Chem. Soc.*, 2012, 134, 6544; (d) M. Arisawa, S. Tanii and M. Yamaguchi, *Chem. Commun.*, 2014, 50, 15267.

7 For reviews, see: (a) H. V. Adcock and P. W. Davies, *Synthesis*, 2012, 3401; (b) X. Huang, S. Klimczyk and N. Mandle, *Synthesis*, 2012, 175.

8 (a) M. Ackermann, J. Bucher, M. Rappold, K. Graf, F. Rominger and A. S. K. Hashmi, *Chem.-Asian J.*, 2013, 8, 1786; (b) M. C. Blanco Jaimes, V. Weingand, F. Rominger and A. S. K. Hashmi, *Chem.-Eur. J.*, 2013, 19, 12504; (c) C.-M. Ting, C.-D. Wang, R. Chaudhuri and R.-S. Liu, *Org. Lett.*, 2011, 13, 1702; (d) F. M. Istrate and F. Gagoz, *Beilstein J. Org. Chem.*, 2011, 7, 878; (e) M. Ueda, A. Sato, Y. Ikeda, T. Miyoshi, T. Naito and O. Miyata, *Org. Lett.*, 2010, 12, 2594; (f) S. Sugita, M. Ueda, N. Doi, N. Takeda and O. Miyata, *Tetrahedron Lett.*, 2016, 57, 1786.

9 For the relevant Au-catalyzed synthesis of seven-membered carbocycles, see: (a) H. Wu, W. Zi, G. Li, H. Lu and F. D. Toste, *Angew. Chem., Int. Ed.*, 2015, 54, 8529; (b) H. J. Bae, B. Baskar, S. E. An, J. Y. Cheong, D. T. Thangadurai, I. Hwang and Y. H. Rhee, *Angew. Chem., Int. Ed.*, 2008, 47, 2263; for the Pt-catalyzed alkoxlation reactions involving the allylic cation, see: (c) A. Fürstner and P. W. Davies, *J. Am. Chem. Soc.*, 2005, 127, 15024; (d) A. Fürstner, F. Stelzer and H. Szillat, *J. Am. Chem. Soc.*, 2001, 123, 11863.

10 For the relevant Au-catalyzed intermolecular hydroalkoxylation/Claissen rearrangement, see: (a) J. Li, L. Lin, B. Hu, P. Zhou, T. Huang, X. Liu and X. Feng, *Angew. Chem., Int. Ed.*, 2017, 56, 885; (b) M. Egi, K. Shimizu, M. Kamiya, Y. Ota and S. Akai, *Chem. Commun.*, 2015, 51, 380; (c) A. Gómez-Suárez, D. Gasperini, S. V. C. Vummaleti, A. Poater, L. Cavallo and S. P. Nolan, *ACS Catal.*, 2014, 4, 2701; (d) J. M. Ketcham, B. Biannic and A. Aponick, *Chem. Commun.*, 2013, 49, 4157; (e) Y. Wang, L. Liu and L. Zhang, *Chem. Sci.*, 2013, 4, 739; (f) Y. Wang, L. Ye and L. Zhang, *Chem. Commun.*, 2011, 47, 7815; for the relevant Au-catalyzed intermolecular
alkoxylation/Claisen rearrangement, see: (g) S. R. Park, C. Kim, D. Kim, N. Thrimurtulu, H.-S. Yeom, J. Jun, S. Shin and Y. H. Rhee, *Org. Lett.*, 2013, **15**, 1166.

11 For recent reviews on ynamide reactivity, see: (a) F. Pan, C. Shu and L.-W. Ye, *Org. Biomol. Chem.*, 2016, **14**, 9456; (b) G. Evan, C. Theunissen and M. Lecomte, *Aldrichimica Acta*, 2015, **48**, 59; (c) X.-N. Wang, H.-S. Yeom, L.-C. Fang, S. He, Z.-X. Ma, B. L. Kedrowski and R. P. Hsung, *Acc. Chem. Res.*, 2014, **47**, 560; (d) K. A. Dekorver, H. Li, A. G. Lohse, R. Hayashi, Z. Lu, Y. Zhang and R. P. Hsung, *Chem. Rev.*, 2010, **110**, 5064; (e) G. Evan, A. Coste and K. Jouvin, *Angew. Chem., Int. Ed.*, 2010, **49**, 2840.

12 (a) W.-B. Shen, Q. Sun, L. Li, X. Liu, B. Zhou, J.-Z. Yan, X. Lu and L.-W. Ye, *Nat. Commun.*, 2017, **8**, 1748; (b) B. Zhou, L. Li, X.-Q. Zhu, J.-Z. Yan, Y.-L. Guo and L.-W. Ye, *Angew. Chem., Int. Ed.*, 2017, **56**, 4015; (c) W.-B. Shen, X.-Y. Xiao, Q. Sun, B. Zhou, X.-Q. Zhu, J.-Z. Yan, X. Lu and L.-W. Ye, *Angew. Chem., Int. Ed.*, 2017, **56**, 605; (d) L. Li, X.-M. Chen, Z.-S. Wang, B. Zhou, X. Liu, X. Lu and L.-W. Ye, *ACS Catal.*, 2017, **7**, 4004; (e) C. Shu, Y.-H. Wang, B. Zhou, X.-L. Li, Y.-F. Ping, X. Lu and L.-W. Ye, *J. Am. Chem. Soc.*, 2015, **137**, 9567; (f) L. Li, B. Zhou, Y.-H. Wang, C. Shu, Y.-F. Pan, X. Lu and L.-W. Ye, *Angew. Chem., Int. Ed.*, 2015, **54**, 8245; (g) A.-H. Zhou, Q. He, C. Shu, Y.-F. Yu, S. Liu, T. Zhao, W. Zhang, X. Lu and L.-W. Ye, *Chem. Sci.*, 2015, **6**, 1265.

13 For details, please see the ESI.†

14 For Brønsted acid-mediated sulfonium [3,3] rearrangement, see: (a) D. Kaldre, I. Klose and N. Maulide, *Science*, 2018, **361**, 664; (b) D. Kaldre, B. Maryasin, D. Kaiser, O. Gajsek, L. González and N. Maulide, *Angew. Chem., Int. Ed.*, 2017, **56**, 2212.

15 For a review on HNTf₂ in organic synthesis, see: (a) W. Zhao and J. Sun, *Chem. Rev.*, 2018, **118**, 10349; (b) K. Takasu, *Synlett*, 2009, 1905; (c) J. Sun, *Triflimide in Encyclopedia of Reagents for Organic Synthesis*, Wiley, Hoboken, 2010, DOI: 10.1002/047084289X rn01222; for selected examples involving the crucial role of Tf₂N−, see: (d) W. Zhao, H. Qian, Z. Li and J. Sun, *Angew. Chem., Int. Ed.*, 2015, **54**, 10005; (e) W. Zhao, Z. Wang and J. Sun, *Angew. Chem., Int. Ed.*, 2012, **51**, 6209; (f) J. Sun and S. A. Kozmin, *J. Am. Chem. Soc.*, 2005, **127**, 13512; (g) K. Ishihara, Y. Hiraiwa and H. Yamamoto, *Chem. Commun.*, 2002, 1564.

16 For a review on the Tf₂NH-catalyzed reaction of ynamides, see: (a) G. Evan, M. Lecomte, P. Thilmany and C. Theunissen, *Synthesis*, 2017, **49**, 3183; for recent leading examples, see: (b) Y. Zhao, C. Wang, Y. Hu and B. Wan, *Chem. Commun.*, 2018, **54**, 3963; (c) Y. Wang, L.-J. Song, X. Zhang and J. Sun, *Angew. Chem., Int. Ed.*, 2016, **55**, 9704; (d) C. Theunissen, B. Métayer, N. Henry, G. Compain, J. Marrot, A. Martin-Mingot, S. Thibaudeau and G. Evan, *J. Am. Chem. Soc.*, 2014, **136**, 12528.

17 For a recent review, see: C. G. Nasveschuk and T. Rovis, *Org. Biomol. Chem.*, 2008, **6**, 240.

18 CCDC 1831051 (2a), 1831053 (2s), 1831054 (2u) and 1864037 (2ah) contains the supplementary crystallographic data for this paper.†

19 G. Alachouzos and A. J. Frontier, *Angew. Chem., Int. Ed.*, 2017, **56**, 15030.

20 J. A. Mulder, R. P. Hsung, M. O. Frederick, M. R. Tracey and C. A. Zifcsak, *Org. Lett.*, 2002, **4**, 1383.

21 E. Stempel and T. Gaich, *Acc. Chem. Res.*, 2016, **49**, 2390.

22 For a possible molecular model of transition state to explain the chirality induction, see the ESI.†

23 For the relevant Brønsted acid-promoted hydrolysis, see: (a) D. Fujino, H. Yorimitsu and A. Osuka, *J. Am. Chem. Soc.*, 2014, **136**, 6255; (b) S. K. Pawar, D. Vasu and R.-S. Liu, *Adv. Synth. Catal.*, 2014, **356**, 2411; (c) S. N. Karad, S. Bhunia and R.-S. Liu, *Angew. Chem., Int. Ed.*, 2012, **51**, 8722.

24 For the relevant proton acid-mediated cationic polyene cyclization, see: S. Kano, T. Yokomatsu, Y. Yuasa and S. Shibuya, *J. Org. Chem.*, 1985, **50**, 3449.